Last reviewed · How we verify
Placebo of Isosorbide Dinitrate
Placebo of Isosorbide Dinitrate is a Small molecule drug developed by Guang'anmen Hospital of China Academy of Chinese Medical Sciences. It is currently FDA-approved for Control arm in clinical trials evaluating isosorbide dinitrate efficacy.
This is a placebo formulation with no active pharmacological mechanism.
This is a placebo formulation with no active pharmacological mechanism. Used for Control arm in clinical trials evaluating isosorbide dinitrate efficacy.
At a glance
| Generic name | Placebo of Isosorbide Dinitrate |
|---|---|
| Sponsor | Guang'anmen Hospital of China Academy of Chinese Medical Sciences |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
A placebo of isosorbide dinitrate contains no active drug substance and produces no direct pharmacological effect. It is used as a control in clinical trials to assess the efficacy of the active isosorbide dinitrate formulation by comparison. Any observed effects are attributable to placebo response rather than drug action.
Approved indications
- Control arm in clinical trials evaluating isosorbide dinitrate efficacy
Common side effects
Key clinical trials
- Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy (PHASE1, PHASE2)
- Reduction of Cesareans by Nitric Oxide (NO) Donors in Post Term Pregnancies (PHASE3)
- Isosorbide Mononitrate and Butylphthalide to Reduce the Risk of Disability in Patients With Acute Lacunar Stroke (IMPACT) (PHASE3)
- Treatment of Orthostatic Intolerance (PHASE1, PHASE2)
- Efficacy and Safety of Isosorbide Oral Solution in Patients With Meniere's Disease (PHASE2, PHASE3)
- Optimized Treatment of Pulmonary Edema or Congestion (PHASE4)
- Nitric Oxide Donor Isosorbide Mono Nitrate for Cervical Ripening in Induction of Labor (PHASE4)
- Termination Of Anembryonic Pregnancy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo of Isosorbide Dinitrate CI brief — competitive landscape report
- Placebo of Isosorbide Dinitrate updates RSS · CI watch RSS
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences portfolio CI
Frequently asked questions about Placebo of Isosorbide Dinitrate
What is Placebo of Isosorbide Dinitrate?
How does Placebo of Isosorbide Dinitrate work?
What is Placebo of Isosorbide Dinitrate used for?
Who makes Placebo of Isosorbide Dinitrate?
What development phase is Placebo of Isosorbide Dinitrate in?
Related
- Manufacturer: Guang'anmen Hospital of China Academy of Chinese Medical Sciences — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Control arm in clinical trials evaluating isosorbide dinitrate efficacy
- Compare: Placebo of Isosorbide Dinitrate vs similar drugs
- Pricing: Placebo of Isosorbide Dinitrate cost, discount & access